# Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)

> **NCT07543796** · PHASE2 · RECRUITING · sponsor: **Beijing Tide Pharmaceutical Co., Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Postoperative Analgesia After Unilateral Hip Arthroplasty

## Interventions

- **DRUG:** TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 doses
- **DRUG:** TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 doses
- **DRUG:** TRD205 Tablets, oral; 1200 mg initial dose, then 600 mg q12h; total 4 doses
- **DRUG:** Celecoxib, oral; 400 mg initial dose, then 200 mg q12h; total 4 doses
- **DRUG:** Matching placebo tablets and capsules, same dosing schedule

## Key facts

- **NCT ID:** NCT07543796
- **Lead sponsor:** Beijing Tide Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2026-06-27
- **Final completion:** 2026-07-27
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07543796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07543796, "Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07543796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*